SCHEMBL2875555

SCHEMBL2875555

O=S(=O)(NCCc1ccccc1OC(F)(F)F)c1cc(Br)ccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.47
HSD17B13 Q7Z5P4 1/20 0.44
ACLY P53396 1/20 0.42
ALPL P05186 2/20 0.41
SLC22A12 Q96S37 3/20 0.41
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PPARG P37231 1/20 0.39
CCR1 P32246 1/20 0.38
ADRA2A P08913 2/20 0.38
NPY5R Q15761 2/20 0.38
MCHR1 Q99705 2/20 0.38
GRIN2B Q13224 1/20 0.38
GAA P10253 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA5A P35218 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2877986 0.85 CA12 (0.54) MGAMMAPTSMN1; SMN2CA12CA1
SCHEMBL2872499 0.79 MGAM (0.46) MGAMHSD17B13SLC22A12MAPTCCR1
SCHEMBL2875837 0.76 LMNA (0.55) SMN1; SMN2GAA
SCHEMBL21550432 0.76 TAAR1 (0.50) SMN1; SMN2CA12CA1CA2CA5A
SCHEMBL2872987 0.75 NR1H2 (0.57)
SCHEMBL2873488 0.75 MGAM (0.47) MGAMHSD17B13MAPT
SCHEMBL2878392 0.74 MGAM (0.45) MGAMHSD17B13MAPT
Tert-Butyl Formate SCHEMBL27751384 0.74 MGAM (0.42) MGAMHSD17B13SLC22A12MAPTCA12
SCHEMBL2878432 0.74 MGAM (0.45) MGAMHSD17B13MAPT
Tert-Butyl Formate SCHEMBL27751385 0.73 MGAM (0.39) MGAMHSD17B13ACLYSLC22A12MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171456-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2021-06-10 US claimed
US-20250136545-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2025-05-01 US disclosed
US-12202790-B2 Sulfonamide derivatives having selective Nox inhibiting activity GLUCOX BIOTECH AB (SE) 2025-01-21 US disclosed
US-20210171456-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2021-06-10 US disclosed
EP-2066628-B1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS SANOFI AVENTIS (FR) 2010-10-20 EP disclosed
US-20090176804-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2009-07-09 US disclosed
EP-2066628-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS Sanofi-Aventis (FR) 2009-06-10 EP disclosed
WO-2008014186-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12202790-B2 Sulfonamide derivatives having selective Nox inhibiting activity NOX4, NOX1, NOX5 MGAM 1807/4885HSD17B13 1591/4885ACLY 2328/4885
US-20210171456-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY NOX4, NOX1, NOX5 MGAM 1703/4885HSD17B13 1827/4885ACLY 2249/4885
US-20250136545-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY NOX4, NOX1, NOX5 MGAM 1703/4885HSD17B13 1827/4885ACLY 2249/4885
US-20090176804-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS PTGER2, PTGDR2, CYSLTR2 MGAM 4301/4885HSD17B13 2206/4885ACLY 4136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.